Tango Therapeutics (TNGX) Research & Development (2020 - 2025)
Historic Research & Development for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $30.8 million.
- Tango Therapeutics' Research & Development fell 735.95% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.0 million, marking a year-over-year decrease of 517.97%. This contributed to the annual value of $143.9 million for FY2024, which is 2493.1% up from last year.
- Latest data reveals that Tango Therapeutics reported Research & Development of $30.8 million as of Q3 2025, which was down 735.95% from $32.8 million recorded in Q2 2025.
- Tango Therapeutics' Research & Development's 5-year high stood at $38.7 million during Q2 2024, with a 5-year trough of $15.0 million in Q1 2021.
- In the last 5 years, Tango Therapeutics' Research & Development had a median value of $28.7 million in 2022 and averaged $28.6 million.
- In the last 5 years, Tango Therapeutics' Research & Development skyrocketed by 6893.74% in 2021 and then tumbled by 1512.65% in 2025.
- Over the past 5 years, Tango Therapeutics' Research & Development (Quarter) stood at $21.6 million in 2021, then surged by 34.47% to $29.1 million in 2022, then rose by 7.73% to $31.3 million in 2023, then increased by 8.29% to $33.9 million in 2024, then decreased by 9.2% to $30.8 million in 2025.
- Its Research & Development was $30.8 million in Q3 2025, compared to $32.8 million in Q2 2025 and $36.4 million in Q1 2025.